Account wins

Share this article:
MedThink Communications has been retained by Salix Pharmaceuticals to launch and promote its newest product under development, an orally disintegrating form of metoclopramide. Salix recently licensed the rights to market the orally disintegrating metoclopramide tablet and will bring the drug to market following approval from the FDA.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.